Analytica's lead product is the PeriCoach™ System - an e-health treatment system for women who suffer Stress Urinary Incontinence. This debilitating condition affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles during pregnancy, childbirth and menopause. It is estimated that by 2030, more than 5 million women in Australia alone will be affected.

PeriCoach™ comprises a novel device, web portal and smartphone app. The device is discreet and works by evaluating activity in pelvic floor muscles. This information is immediately transmitted to a smartphone. From there it can be uploaded and accessed by physicians via cloud based portal.

This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition.

PeriCoach™ is unique. The product has has Australia regulatory clearance and is available from the website. The product also has CE-marking and product launches are anticipated in Europe and the US in 2015*. The US market for incontinence pads is $5 billion pa.


Analytica is also commercialising the AutoStart™ Infusion System. This is a burette with improved safety and cost reduction features. It is targeting a $3 billion pa global market, and has FDA approval.

* The PeriCoach is pending 510(k) clearance from the USFDA.

Investment Information

Analytica Limited (ABN 12 006 464 866) is a Brisbane-based public company listed on the Australian Stock Exchange (ASX Code: ALT). For more information, see About Us and ASX Releases.

Recent News

Announcements are also available as an RSS feed